Enzymotec Ltd. Reports Commercial Introduction of Its Innovative Omega PC(TM) Advanced Fish Oil Product
23 June 2014 - 10:47PM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients, announced
today the launch of Omega PC™, a new, premium fish oil-based
omega-3 product.
Omega PC™ is a wild, cold fish extract, containing omega-3 fatty
acids bound to phospholipids (PL) and triglycerides (TG). The first
commercial sale of this innovative product took place last week in
preparation for customer launch.
"We are very pleased with the launch of Omega PC™ and believe
this will take us one step further towards creating a new golden
standard for fish oil consumption," said Dr. Ariel Katz, President
and Chief Executive Officer of Enzymotec Ltd. "Our strategic
partnership with Polar Omega enables two significant players in the
global omega-3 market to create a product that will deliver new
health benefits to consumers. We believe that this new advanced
fish oil product should help drive growth in the Omega 3 fish oil
market, which became stagnant due to commoditization and lack of
innovation."
Omega PC™ offers the following benefits compared to current
omega-3 fish oil:
- Omega-3 fatty acids bound to phospholipids that have been shown
to be absorbed better than triglyceride bound Omega-3
- Better absorption leads to better efficacy and to higher
accumulation of omega-3 fatty acids in target organs
- The omega-3 oil in Omega PC™ better represents the omega-3 oil
in wild cold water fish as it contains omega 3 fatty acids bound to
both TG and phospholipids.
- Reduced fishy burps.
The production of Omega PC™ follows the strictest sustainability
protocols of the International Fishmeal and Fish Oil Organization
(IFFO).
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty
lipid-based products and solutions. The Company develops,
manufactures and markets innovative bio- active lipid ingredients,
as well as final products, based on sophisticated processes and
technologies. For more information, visit www.enzymotec.com.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: we depend on third parties to
obtain raw materials, in particular krill, necessary for the
production of our products; a high proportion of the sales of our
INFAT® product is sold to end users by a single company in China;
we are subject to a degree of customer concentration and our
customers do not enter into long-term purchase commitments with us;
we may be required to pay royalties on sales of our krill products
in North America and Australia; we have in the past, and may in the
future, become subject to litigation regarding intellectual
property rights or other matters; our offering of products as
''medical foods'' in the United States may be challenged by
regulatory authorities; we rely on our Swedish joint venture
partner to manufacture INFAT®, and certain matters related to the
joint venture are the subject of disagreement; we are dependent on
a single facility that houses the majority of our operations; we
may be impacted by delays in manufacturing as we expand our
capacity; we may not be able to expand our production or processing
capabilities or satisfy growing demand; our gross profits may be
adversely affected if we are only able to obtain lower quality
krill meal; our ability to obtain krill may be affected by
conservation regulation or initiatives; our product development
cycle is lengthy and uncertain, and our development or
commercialization efforts for our products may be unsuccessful; we
are subject to significant and increasing government regulations
regarding the sale and marketing of our products; we may not be
able to protect our proprietary technology or prevent its
unauthorized use by third parties; and other factors discussed
under the heading "Risk Factors" in the Company's Form 20-F filed
with the Securities and Exchange Commission on February 13, 2014.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
-or-
John Mills
310-954-1105
John.Mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2024 to Aug 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Aug 2023 to Aug 2024